The same favorable results in differentiating between the TNBC and HER2 positive breast cancer were obtained in a retrospective analysis by Dogan and collaborated on a lot of 532 cases of breast cancers in 519 patients with molecular markers available [62,63]. This evidence concerns the gene ERBB2 and breast carcinoma.